Molecular modeling-based inclusion mechanism and stability studies of doxycycline and hydroxypropyl-β-cyclodextrin complex for ophthalmic delivery

AAPS PharmSciTech

Volumn 14, Issue 1, 2013, Pages 10-18

  Zhang, Haohao ^a   Chen, Meiwan ^b   He, Zixin ^a   Wang, Zhouhua ^a   Zhang, Meimei ^a   He, Zhouyang ^a   Wan, Qian ^c   Liang, Dan ^c   Repka, Michael A ^d   Wu, Chuanbin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b University of Macau   (Macao)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

doxycycline; hydroxypropyl cyclodextrin; inclusion mechanism; molecular modeling; stability

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; DOXYCYCLINE; MAGNESIUM ION;

ANTIBACTERIAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CHELATION; COMPLEX FORMATION; CORNEA NEOVASCULARIZATION; DISK DIFFUSION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; ESCHERICHIA COLI; EYE INFECTION; HETERONUCLEAR NUCLEAR MAGNETIC RESONANCE; IN VITRO STUDY; INTRAOCULAR DRUG ADMINISTRATION; MOLECULAR INTERACTION; MOLECULAR MODEL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCANNING ELECTRON MICROSCOPY; SOLID STATE; STAPHYLOCOCCUS AUREUS; ULTRAVIOLET SPECTROSCOPY;

ADMINISTRATION, OPHTHALMIC; ANTI-BACTERIAL AGENTS; BETA-CYCLODEXTRINS; DOXYCYCLINE; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING; MODELS, MOLECULAR; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84878545860     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9877-1     Document Type: Article

References (36)

1. Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006;98(19):1375-82.
2. Smith VA, Cook SD. Doxycycline-a role in ocular surface repair. Br J Ophthalmol. 2004;88(5):619-25.
3. Libinson GS, Ushakova TA. Doxycycline. Stability in solutions. Pharm Chem J. 1976;10(8):1076-8.
4. Carrier RL, Miller LA, Ahmed M. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release. 2007;123(2):78-99.
5. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329(1-2):1-11.
6. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007;59(7):645-66.
7. Mady FM, Abou-Taleb AE, Khaled KA, Yamasaki K, Iohara D, Taguchi K, et al. Evaluation of carboxymethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine. Int J Pharm. 2010;397(1-2):1-8.
8. Stella VJ, Rao VM, Zannou EA, Zia V. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev. 1999;36(1):3-16.
9. Cal K, Centkowska K. Use of cyclodextrins in topical formulations: practical aspects. Eur J Pharm Biopharm. 2008;68(3):467-78.
10. Armstrong WW, Neck M. Oxytetracycline compositions. US patent. 1976;646,295.
11. Nosworthy MM, Ferry G. Doxycycline parenteral compositions. US patent. 1976;477,703.
12. Su WR, Li ZR, Lin ML, Li YP, He ZX, Wu CB, et al. The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats. Graefes Arch Clin Exp Ophthalmol. 2011;249(3):421-7.
13. Cho HJ, Balakrishnan P, Shim WS, Chung SJ, Shim CK, Kim DD. Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron-cyclodextrin complex and carboxymethylcellulose for intranasal delivery. Int J Pharm. 2010;400(1-2):59-65.
14. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85(10):1017-25.
15. de Paula WX, Denadai AML, Santoro MM, Braga ANG, Santos RAS, Sinisterra RD. Supramolecular interactions between losartan and hydroxypropyl-beta-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies. Int J Pharm. 2011;404(1-2):116-23.
16. Mura P, Bettinetti G, Melani F, Manderioli A. Interaction between naproxen and chemically modified [beta]-cyclodextrins in the liquid and solid state. Eur J Pharm Sci. 1995;3(6):347-55.
17. Yap KL, Liu X, Thenmozhiyal JC, Ho PC. Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis. Eur J Pharm Sci. 2005;25(1):49-56.
18. Xing SK, Zhang C, Ai HQ, Zhao Q, Zhang Q, Sun DZ. Theoretical study of the interactions of beta-cyclodextrin with 2 ′-hydroxyl-5 ′-methoxyacetophone and two of its isomers. J Mol Liq. 2009;146(1-2):15-22.
19. Shi JH, Ding ZJ, Hu Y. Theoretical study on chiral recognition mechanism of methyl mandelate enantiomers on permethylated beta-cyclodextrin. J Mol Model. 2012;18(2):803-13.
20. Chen MW, Pan X, Wu HM, Han K, Xie XB, Wedge DE, et al. Preparation and anti-bacterial properties of a temperature-sensitive gel containing silver nanoparticles. Pharmazie. 2011;66(4):272-7.
21. Rios JL, Recio MC, Villar A. Screening methods for natural products with antimicrobial activity: a review of the literature. J Ethnopharmacol. 1988;23(2-3):127-49.
22. He ZX, Wang ZH, Zhang HH, Pan X, Su WR, Liang D, et al. Doxycycline and hydroxypropyl-β-cyclodextrin complex in poloxamer thermal sensitive hydrogel for ophthalmic delivery. Acta Pharmacol Sin B. 2011;1(4):254-60.
23. Gibaud S, Ben ZS, Mutzenhardt P, Fries I, Astier A. Melarsoprol- cyclodextrins inclusion complexes. Int J Pharm. 2005;306(1-2):107-21.
24. Zhao M, Wang H, Yang B, Tao H. Identification of cyclodextrin inclusion complex of chlorogenic acid and its antimicrobial activity. Food Chem. 2010;120(4):1138-42.
25. Yang B, Lin J, Chen Y, Liu Y. Artemether/hydroxypropyl-beta-cyclodextrin host-guest system: characterization, phase-solubility and inclusion mode. Bioorg Med Chem. 2009;17(17):6311-7.
26. Torri G, Bertini S, Giavana T, Guerrini M, Puppini N, Zoppetti G. Inclusion complex characterization between progesterone and hydroxypropyl-beta- cyclodextrin in aqueous solution by NMR study. J Incl Phenom Macrocycl Chem. 2007;57(1-4):317-21.
27. Jullian C, Cifuentes C, Alfaro M, Miranda S, Barriga G, Olea-Azar C. Spectroscopic characterization of the inclusion complexes of luteolin with native and derivatized beta-cyclodextrin. Bioorg Med Chem. 2010;18(14):5025-31.
28. Li JS, Xiao HN, Li JH, Zhong YP. Drug carrier systems based on water-soluble cationic beta-cyclodextrin polymers. Int J Pharm. 2004;278(2):329-42.
29. 1H-benzimidazole/2-hydroxypropyl- beta-cyclodextrin association: characterization, molecular modeling studies, and in vivo anthelminthic activity. Bioorg Med Chem. 2011;19(2):789-97.
30. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res. 2000;33(12):889-97.
31. Jullian C, Orosteguis T, Perez-Cruz F, Sanchez P, Mendizabal F, Olea-Azar C. Complexation of morin with three kinds of cyclodextrin. A thermodynamic and reactivity study. Spectrochim Acta A Mol Biomol Spectrosc. 2008;71(1):269-75.
32. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev. 1998;98(5):1743-54.
33. Skulason S, Ingolfsson E, Kristmundsdottir T. Development of a simple HPLC method for separation of doxycycline and its degradation products. J Pharm Biomed Anal. 2003;33(4):667-72.
34. Newman EC, Frank CW. Circular dichroism spectra of tetracycline complexes with Mg+2 and Ca+2. J Pharm Sci. 1976;65(12):1728-32.
35. Lambs L, Venturim M, Révérend BDL, Kozlowski H, Berthon G. Metal ion-tetracycline interactions in biological fluids: part 8. Potentiometric and spectroscopic studies on the formation of Ca (II) and Mg (II) complexes with 4-dedimethylamino-tetracycline and 6-desoxy-6-dem. J Inorg Biochem. 1988;33(3):193-209.
36. Silva PP, Guerra W, Silveira JN, Ferreira AMC, Bortolotto T, Fischer FL, et al. Two new ternary complexes of copper(II) with tetracycline or doxycycline and 1,10-phenanthroline and their potential as antitumoral: cytotoxicity and DNA cleavage. Inorg Chem. 2011;50(14):6414-24.